BioCryst Pharmaceuticals, Inc.
Durham
NC
27703
United States
605 articles about BioCryst Pharmaceuticals, Inc.
-
Ebola Clinical Trials: Big Name Players In The Ebola Race
10/28/2014
-
Biocryst Pharmaceuticals Release: RAPIVABâ„¢ Trial Results For The Treatment Of Influenza To Be Presented At IDWeek 2014
10/8/2014
-
Biocryst Pharmaceuticals Announces Late Breaker Presentation Of Opus-1 Phase 2 Trial Results At The 23rd EADV Congress
10/7/2014
-
Biocryst Pharmaceuticals Receives Additional National Institute of Allergy And Infectious Diseases (NIAID) Funding For Manufacture And Development Of BCX4430 To Treat Hemorrhagic Virus Diseases
9/18/2014
-
Biocryst Pharmaceuticals Announces RAPIVABâ„¢ Trial Results For The Treatment Of Influenza At The ICAAC 2014 Meeting
9/8/2014
-
Biocryst Pharmaceuticals Participates In World Health Organization Consultation On Potential Ebola Therapies
9/4/2014
-
Biocryst Pharmaceuticals To Present At Rodman & Renshaw Conference
9/3/2014
-
Biocryst Pharmaceuticals To Present Peramivir Trial Results For The Treatment Of Influenza At The ICAAC 2014 Meeting
9/2/2014
-
Biocryst Pharmaceuticals To Launch NHP Ebola Drug Safety, Efficacy Studies "Within Weeks"
8/29/2014
-
Biocryst Pharmaceuticals Expected To Jump Into Ebola Race In A Few Weeks
8/29/2014
-
Biocryst Pharmaceuticals Receives Additional National Institute of Allergy And Infectious Diseases (NIAID) Funding To Advance Development Of BCX4430 To Treat Hemorrhagic Fever Virus Diseases
8/13/2014
-
Biocryst Pharmaceuticals Reports Second Quarter 2014 Financial Results
8/5/2014
-
Biocryst Pharmaceuticals To Announce Second Quarter 2014 Financial Results August 5
7/22/2014
-
Biocryst Pharmaceuticals Announces Exercise Of Over-Allotment Option And Completion Of Public Offering
6/3/2014
-
Biocryst Pharmaceuticals Prices Public Offering Of Common Stock
5/29/2014
-
Biocryst Pharmaceuticals Commences Public Offering Of Common Stock
5/28/2014
-
Biocryst Pharmaceuticals To Announce Results From The BCX4161 Opus-1 Phase 2 Trial For Hereditary Angioedema May 27
5/27/2014
-
Biocryst Pharmaceuticals Announces Positive Results From Opus-1, A Phase 2 Trial Of BCX4161 For The Prophylactic Treatment Of Hereditary Angioedema
5/27/2014
-
Biocryst Pharmaceuticals To Present At Bank of America Merrill Lynch 2014 Healthcare Conference
5/9/2014
-
Biocryst Pharmaceuticals Reports First Quarter 2014 Financial Results
5/8/2014